Beck Capital Management LLC boosted its holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 5.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,383 shares of the company’s stock after buying an additional 1,109 shares during the period. Beck Capital Management LLC owned approximately 0.30% of VanEck Pharmaceutical ETF worth $2,127,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also bought and sold shares of the company. Optimum Investment Advisors purchased a new stake in shares of VanEck Pharmaceutical ETF in the second quarter worth about $27,000. GPS Wealth Strategies Group LLC bought a new position in VanEck Pharmaceutical ETF in the 2nd quarter valued at $42,000. CWM LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the 2nd quarter valued at $55,000. International Assets Investment Management LLC bought a new position in shares of VanEck Pharmaceutical ETF in the second quarter worth $86,000. Finally, Comerica Bank raised its position in shares of VanEck Pharmaceutical ETF by 39.4% in the first quarter. Comerica Bank now owns 1,337 shares of the company’s stock worth $121,000 after buying an additional 378 shares in the last quarter.
VanEck Pharmaceutical ETF Stock Performance
NASDAQ:PPH opened at $90.14 on Monday. VanEck Pharmaceutical ETF has a 52-week low of $77.61 and a 52-week high of $99.51. The stock has a fifty day moving average of $91.95 and a 200 day moving average of $93.03. The firm has a market capitalization of $666.13 million, a price-to-earnings ratio of 21.04 and a beta of 0.72.
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
See Also
- Five stocks we like better than VanEck Pharmaceutical ETF
- What Do S&P 500 Stocks Tell Investors About the Market?
- 2 Home Improvement Leaders Building Momentum for Upside
- Conference Calls and Individual Investors
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- Which Wall Street Analysts are the Most Accurate?
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
